glp-1 and breast cancer Drugs May Improve Survival Rates. Here's How Ending Breast Cancer Forever |

availability and eligibility criteria may vary by local Integrated Care System (ICS), so your GP can advise on what is available in your area For eligible individuals, pharmacological treatments may be appropriate

Hydrogen sulfide inhibits NLRP3 inflammasome activation and reduces cytokine production both in vitro and in a mouse model of inflammation

In the US these products are not intended to diagnose, treat, cure, or prevent any disease

Eli Lilly submitted the orforglipron NDA to the FDA in Q1 2026 following ATTAIN Phase 3 trial data showing 14.7% body weight reduction at 45mg positioning the worlds first oral small molecule GLP-1 receptor agonist for obesity for anticipated FDA approval in late 2026 or 2027

If GLP-1 therapy is right for you, we'll help you do it safely and effectively